UNSPSC 51111754: Mitonafide

This classification denotes an intercalating agent with the molecular formula C16H15N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 06Q0V17SI9, chemically known as 2-((dimethylamino)ethyl)-2,3-dihydro-5-nitro-2-azaphenalen-1,3-dion but generally known as mitonafide, which bears US NIH Compound Identifier 41202. European Medicines Agency schedules Mitonafide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09007MIG.

UNSPSC 51111754 Mitonafide, a Commodity code, does not align with the state and local procurement activity posted under it. The recent opportunities record shows two unrelated procurements: an Illinois Department of Public Health pharmaceutical warehouse contract for antibiotic tablets (Doxycycline Hyclate and Ciprofloxacin Hydrochloride) awarded to Chartwell Rx LLC in August 2026, and a Seminole County, Florida IFB for Naloxone and drug deactivation systems posted in June 2026. Neither procurement involves mitonafide or a related therapeutic agent. The code shows little relevant recent activity — the two posted opportunities are classified under it but do not match its stated scope.

The geographic activity spans at least Illinois and Florida, though the limited number of recent records provides insufficient basis to characterize broader state or regional concentration. The Illinois award was completed in August 2026 with no open solicitation phase; the Seminole County IFB closed in July 2026 and did not specify set-aside designations. Without additional UNSPSC-aligned opportunities in the recent record, no recommendation for pursuit can be grounded in actual state and local demand for this commodity.